Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center and validation in the Memorial Sloan Kettering Cancer Center Cohort.
Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Zijing Wang(Qingdao University), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), Qiao Li(Guangzhou University of Chinese Medicine), Qing Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yiqun Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Luo(Chongqing University of Posts and Telecommunications), Yimeng Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Pin Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiayu Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Shaoyan Lin(Nanjing Agricultural University), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruigang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 1
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k